127 results
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
that may be incurred beyond the first quarter of 2024, as both cannot be reliably forecasted.
About AbbVie
AbbVie's mission is to discover
424B5
ABBV
Abbvie Inc
26 Feb 24
Prospectus supplement for primary offering
6:12am
in its mission to transform standards of care across psychiatric and neurological disorders.
The foregoing description of the Cerevel acquisition
424B5
k3y pkzrit2bxa
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
utw d19ejp
20 Feb 24
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
9:00am
8-K
EX-99.1
6nrarfz4nj pmewv
12 Feb 24
AbbVie Completes Acquisition of ImmunoGen
7:49am
8-K
EX-99.1
cg707mqvz1cyfwjn4hv
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
EX-99.1
rf1gw2hnubaw4
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.1
z7dpxze8u
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.1
z7sqc 1iiwu1m7rsm
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
2i1 bfuhjvnzx9hbc
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
8-K
EX-99.1
y6iiki 0l
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am
8-K
EX-99.1
3opil8mum
28 Oct 22
AbbVie Reports Third-Quarter 2022 Financial Results
7:48am